Patents by Inventor Frank Rebers
Frank Rebers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11915922Abstract: A silicon wafer for an electronic component, having an epitaxially grown silicon layer on a carrier substrate and the silicon layer is removed as a silicon wafer from the carrier substrate, in which at least one p-dopant and at least one n-dopant are introduced into the silicon layer during the epitaxial growth. The dopants are introduced into the silicon layer such that the silicon layer is formed having an electrically active p-doping and an electrically active n-doping, each greater than 1×1014 cm?3.Type: GrantFiled: March 18, 2021Date of Patent: February 27, 2024Assignee: NexWafe GmbHInventors: Stefan Reber, Kai Schillinger, Frank Siebke
-
Patent number: 9102733Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.Type: GrantFiled: December 1, 2010Date of Patent: August 11, 2015Assignee: Roche Palo Alto LLCInventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
-
Publication number: 20110086026Abstract: An antibody binding to IL-13R?1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.Type: ApplicationFiled: July 26, 2010Publication date: April 14, 2011Inventors: Josef Endl, Maria Elena Fuentes, Yvo Graus, Adelbert Grossmann, Sebastian Neumann, Paul Parren, Frank Rebers, Joerg Thomas Regula, Ralf Schumacher, Stefan Seeber, Jan Olaf Stracke, Kay-Gunnar Stubenrauch, Jan Van De Winkel, Martine Van Vugt, Sandra Vereecken-Verploegen
-
Publication number: 20110070239Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.Type: ApplicationFiled: December 1, 2010Publication date: March 24, 2011Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
-
Patent number: 7868141Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.Type: GrantFiled: December 5, 2008Date of Patent: January 11, 2011Assignee: Roche Palo Alto LLCInventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
-
Patent number: 7824684Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).Type: GrantFiled: April 27, 2010Date of Patent: November 2, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
-
Patent number: 7807158Abstract: The instant specification discloses an antibody binding to IL-13R?1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of this antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9, and this antibody is useful in the treatment of asthma and allergic diseases.Type: GrantFiled: January 3, 2006Date of Patent: October 5, 2010Assignee: Roche Palo Alto LLCInventors: Josef Endl, Maria Elena Fuentes, Yvo Graus, Adelbert Grossmann, Sebastian Neumann, Paul Parren, Frank Rebers, Joerg Thomas Regula, Ralf Schumacher, Stefan Seeber, Jan Olaf Stracke, Kay-Gunnar Stubenrauch, Jan Van De Winkel, Martine Van Vugt, Sandra Vereecken-Verploegen
-
Publication number: 20100209423Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).Type: ApplicationFiled: April 27, 2010Publication date: August 19, 2010Inventors: YVO GRAUS, JACQUES HIMBER, MIRANDA JANSEN-MOLENAAR, DOROTHEE KLING, ERHARD KOPETZKI, PAUL PARREN, FRANK REBERS, BEAT STEINER, ANNE STERN, PAMELA STREIN, KAY-GUNNAR STUBENRAUCH, JAN VAN DE WINKEL, MARTINE VAN VUGT
-
Patent number: 7754867Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).Type: GrantFiled: June 10, 2009Date of Patent: July 13, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
-
Publication number: 20100166740Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.Type: ApplicationFiled: December 5, 2008Publication date: July 1, 2010Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van de Winkel, Martine Van Vugt
-
Publication number: 20090311779Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).Type: ApplicationFiled: June 10, 2009Publication date: December 17, 2009Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
-
Publication number: 20090275126Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.Type: ApplicationFiled: July 17, 2009Publication date: November 5, 2009Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vriesema-van Vugt
-
Patent number: 7579157Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing the antibodies, and uses for the antibodies are disclosed. Antibodies against IGF-IR are implicated in antitumor therapy.Type: GrantFiled: July 8, 2004Date of Patent: August 25, 2009Assignee: Hoffmann-La Roche Inc.Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vriesema-van Vugt
-
Patent number: 7572897Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Antibodies against IGF-IR are implicated in antitumor therapy.Type: GrantFiled: October 9, 2007Date of Patent: August 11, 2009Assignee: Hoffman-La Roche Inc.Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vriesema-van Vugt
-
Patent number: 7563441Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).Type: GrantFiled: April 8, 2005Date of Patent: July 21, 2009Assignee: Hoffman-La Roche Inc.Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
-
Patent number: 7501496Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.Type: GrantFiled: September 16, 2005Date of Patent: March 10, 2009Assignee: Roche Palo Alto LLCInventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
-
Publication number: 20080132686Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.Type: ApplicationFiled: October 9, 2007Publication date: June 5, 2008Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vriesema-van Vugt
-
Patent number: RE43568Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).Type: GrantFiled: July 21, 2011Date of Patent: August 7, 2012Assignee: Hoffmann-La Roche Inc.Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan Van de Winkel, Martine Van Vugt
-
Patent number: RE44359Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).Type: GrantFiled: May 15, 2012Date of Patent: July 9, 2013Assignee: Hoffmann-La Roche IncInventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Braemer, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
-
Patent number: RE44389Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).Type: GrantFiled: October 17, 2012Date of Patent: July 23, 2013Assignee: Hoffman-La Roche Inc.Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Braemer, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt